查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1565676

卡波西氏肉瘤市場，按產品類型、治療、診斷、最終用戶、國家和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

Kaposi Sarcoma Market, By Product Type, By Treatment, By Diagnostic, By End User, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 288 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告要點

2023年卡波西氏肉瘤市場規模為1.403億美元，2024年至2032年複合年成長率為4.90%。

卡波西氏肉瘤市場-市場動態

與愛滋病毒相關的卡波西氏肉瘤的創新療法促進了市場成長。

HIV 相關卡波西氏肉瘤 (KS) 的創新治療方法可透過改善患者治療效果和增加對標靶治療的需求來推動市場成長。抗逆轉錄病毒療法和 KS 特異性療法的進步提高了生活品質和存活率，促進了該領域的更大投資和發展。美國癌症協會 2022 年發表的研究。研究表明，針對愛滋病毒相關卡波西氏肉瘤的新療法的引入導致該疾病的年發病率顯著下降。具體而言，從 2010 年到 2022 年，HIV 陽性個體中卡波西氏肉瘤的發生率下降了約 40%，這主要歸功於抗逆轉錄病毒療法和標靶治療的進步。

卡波西氏肉瘤市場 - 關鍵見解

根據我們的研究分析師分享的分析，預計全球市場在預測期內（2024-2032）每年將以 4.90% 左右的複合年成長率成長

根據產品類型細分，流行病（愛滋病相關）卡波西氏肉瘤預計將在 2023 年顯示最大的市場佔有率

根據治療細分，高效抗逆轉錄病毒療法 (HAART) 是 2023 年的主導類型

根據診斷細分，活體組織切片是 2023 年的主導類型

按地區分類，北美是 2023 年的主要收入來源

卡波西氏肉瘤市場-細分分析：

全球卡波西氏肉瘤市場根據產品類型、治療、診斷、最終用戶和地區進行細分。

根據產品類型，市場分為三類：流行性（愛滋病相關）卡波西氏肉瘤、經典（地中海）卡波西氏肉瘤、地方性（非洲）卡波西氏肉瘤、醫源性（移植相關）卡波西肉瘤。卡波西氏肉瘤市場中最突出的部分是流行性（愛滋病相關）卡波西氏肉瘤。由於愛滋病毒/愛滋病的高盛行率，這種形式的疾病已成為最嚴重的疾病，愛滋病毒/愛滋病是發展卡波西氏肉瘤的主要危險因子。隨著全球愛滋病流行，這種類型的卡波西氏肉瘤仍然是一個嚴重的問題，推動了對有針對性的治療和研究的需求。其他類型雖然很重要，但與流行病變種的流行程度和影響並不相符。

根據治療方法，市場分為六類：高效抗逆轉錄病毒治療（HAART）、放射治療、手術、冷凍手術、化學治療、生物治療。卡波西氏肉瘤市場最突出的治療領域是高效抗逆轉錄病毒療法（HAART）。 HAART 很重要，因為它解決了潛在的愛滋病毒/愛滋病感染，而愛滋病毒/愛滋病感染是卡波西氏肉瘤的主要危險因子。透過HAART有效管理愛滋病毒可以透過控制病毒和減少相關併發症的發生率來顯著改善卡波西氏肉瘤的治療結果。雖然放射治療、手術和化療等其他治療方法也很重要，但 HAART 在控制與愛滋病相關的卡波西氏肉瘤的根本原因方面的作用使其成為主要方法。

卡波西氏肉瘤市場-地理洞察

卡波西氏肉瘤 (KS) 治療的北美市場受到幾個關鍵因素的影響。 KS 的流行主要與愛滋病毒/愛滋病有關，影響市場動態，大多數病例發生在美國和加拿大。抗病毒療法 (ART) 的進步改善了 KS 治療結果，減少了市場對特定 KS 治療的需求。然而，由於病例持續存在和復發，對有效治療的需求仍然存在。標靶治療和臨床試驗的研究和開發正在促進市場成長。主要製藥公司和研究機構的存在促進了新療法的開發。監管框架、醫療保健政策和醫療保健服務的取得在塑造市場格局方面也發揮著至關重要的作用。總體而言，雖然市場是利基市場，但它得到了持續創新和對改善患者治療結果的關注的支持。

卡波西氏肉瘤市場-競爭格局：

卡波西氏肉瘤市場由吉利德科學公司、百時美施貴寶公司、默克公司和輝瑞公司等主要參與者推動，這些公司深入參與愛滋病毒/愛滋病和腫瘤治療。其他著名公司，如諾華公司、羅氏控股公司和禮來公司，透過他們的腫瘤學研究做出了貢獻。市場動態包括關注抗病毒、標靶和免疫療法，並在研發方面進行大量投資。監管挑戰和卡波西氏肉瘤的罕見性影響了市場成長。機會在於個人化和聯合療法。治療策略的持續創新和進步塑造了競爭格局。

最新進展：

2024年7月，美國FDA批准了ForDoz的注射液，其中含有脂質體形式的鹽酸阿黴素，用於治療某些癌症。與傳統的阿黴素相比，該配方旨在改善藥物的傳遞並減少副作用。

2023 年 2 月，北卡羅來納大學醫學院的研究人員發現了一種蛋白質，可以幫助 Epstein-Barr 病毒 (EBV) 和卡波西氏肉瘤相關皰疹病毒 (KSHV) 引起疾病和傳播。

目錄

第1章：卡波西氏肉瘤市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 卡波西氏肉瘤市場片段（按產品類型）
    • 卡波西氏肉瘤治療市場片段
    • 卡波西氏肉瘤市場片段（按診斷）
    • 最終用戶的卡波西氏肉瘤市場片段
    • 卡波西氏肉瘤市場片段（按國家/地區）
    • 卡波西氏肉瘤市場片段（按地區）
  • 競爭洞察

第 3 章：卡波西氏肉瘤主要市場趨勢

  • 卡波西氏肉瘤市場促進因素
    • 市場促進因素的影響分析
  • 卡波西氏肉瘤市場限制
    • 市場限制影響分析
  • 卡波西氏肉瘤市場機會
  • 卡波西氏肉瘤市場未來趨勢

第 4 章：卡波西氏肉瘤產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：卡波西氏肉瘤市場：COVID-19 影響分析

  • COVID-19 之前的影響分析
  • COVID-19 後影響分析
    • 表現最佳的市場區隔
    • 邊際成長市場區隔
    • 最寬鬆的市場區隔
    • 邊際損失市場區隔

第 6 章：卡波西氏肉瘤市場格局

  • 2023 年卡波西氏肉瘤市佔率分析
  • 按主要製造商分類的故障數據
    • 既有參與者分析
    • 新興參與者分析

第 7 章：卡波西氏肉瘤市場 - 按產品類型

  • 概述
    • 按產品類型分類的細分市場佔有率分析
    • 流行性（愛滋病相關）卡波西氏肉瘤
    • 經典（地中海）卡波西氏肉瘤
    • 地方性（非洲）卡波西氏肉瘤
    • 醫源性（移植相關）卡波西氏肉瘤

第 8 章：卡波西氏肉瘤市場 - 按治療

  • 概述
    • 按處理方式分類的細分市場佔有率分析
    • 高效抗逆轉錄病毒療法（HAART）
    • 放射治療
    • 手術
    • 冷凍手術
    • 化療
    • 生物療法

第 9 章：卡波西氏肉瘤市場 - 透過診斷

  • 概述
    • 透過診斷進行細分市場佔有率分析
    • 支氣管鏡檢查
    • 胃腸內視鏡檢查
    • 活體組織切片
    • 其他

第 10 章：卡波西氏肉瘤市場 - 按最終用戶

  • 概述
    • 按處理方式分類的細分市場佔有率分析
    • 醫院
    • 居家護理
    • 其他

第 11 章：卡波西氏肉瘤市場 - 按地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 卡波西氏肉瘤北美主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按產品類型）
    • 北美市場規模與預測（以不同處理方式）
    • 北美市場規模和預測（按診斷）
    • 北美市場規模和預測（按最終用戶）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 卡波西氏肉瘤歐洲主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模和預測（按產品類型）
    • 歐洲市場規模與預測（按處理方式）
    • 歐洲市場規模和預測（按診斷）
    • 歐洲市場規模和預測（按最終用戶）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 卡波西氏肉瘤亞太地區主要製造商
    • 亞太地區市場規模與預測（按國家）
    • 亞太地區市場規模與預測（依產品類型）
    • 亞太地區市場規模與預測（以不同處理方式）
    • 亞太地區市場規模和預測（按診斷）
    • 亞太地區市場規模和預測（按最終用戶）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 卡波西氏肉瘤拉丁美洲主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模與預測（按產品類型）
    • 拉丁美洲市場規模與預測（以不同處理方式）
    • 拉丁美洲市場規模與預測（按診斷）
    • 拉丁美洲市場規模和預測（按最終用戶）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 卡波西氏肉瘤中東和非洲主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（按產品類型）
    • 中東及非洲市場規模及預測（依不同處理方式）
    • 中東和非洲市場規模及預測（按診斷）
    • 中東和非洲市場規模及預測（按最終用戶）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 12 章：主要供應商分析 - 卡波西氏肉瘤產業

  • 競爭儀表板
  • 公司簡介
    • Gilead Sciences
    • Bristol-Myers Squibb
    • Merck & Co.
    • Pfizer Inc.
    • Novartis AG
    • Roche Holding AG
    • Eli Lilly and Company
    • Amgen Inc.
    • Celgene Corporation (now part of Bristol-Myers Squibb)
    • AbbVie Inc.
    • Johnson & Johnson
    • Regeneron Pharmaceuticals
    • Incyte Corporation
    • Sandoz (a Novartis division)
    • Alimera Sciences

第 13 章：360 度分析師視角

第 14 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV3886

REPORT HIGHLIGHT

Kaposi Sarcoma Market size was valued at USD 140.30 million in 2023, expanding at a CAGR of 4.90% from 2024 to 2032.

Kaposi sarcoma (KS) is a rare and often aggressive cancer that originates from the cells lining blood vessels and lymphatic vessels. It is characterized by the development of abnormal growths or tumors on the skin, in the mouth, or internal organs. KS is most commonly associated with human herpesvirus 8 (HHV-8) infection and is frequently seen in individuals with weakened immune systems, such as those with HIV/AIDS. The market for Kaposi sarcoma treatments includes pharmaceuticals, such as antiretroviral drugs and chemotherapy agents, as well as targeted therapies and immunotherapies. The market dynamics are influenced by factors such as disease prevalence, advancements in treatment, and the availability of innovative therapies.

Kaposi Sarcoma Market- Market Dynamics

Innovative treatments for HIV-related Kaposi Sarcoma boosting market growth.

Innovative treatments for HIV-related Kaposi Sarcoma (KS) are driving growth in the market by improving patient outcomes and increasing demand for targeted therapies. Advances in antiretroviral therapies and KS-specific treatments enhance the quality of life and survival rates, prompting greater investment and development in this sector. 2022 study published by the American Cancer Society. The study revealed that the introduction of novel therapies for HIV-related Kaposi Sarcoma has led to a significant decline in the annual incidence rate of the disease. Specifically, the incidence of Kaposi Sarcoma among HIV-positive individuals decreased by approximately 40% from 2010 to 2022, attributed largely to advancements in antiretroviral therapies and targeted treatments.

Kaposi Sarcoma Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.90% over the forecast period (2024-2032)

Based on product type segmentation, Epidemic (AIDS Associated) Kaposi Sarcoma was predicted to show maximum market share in the year 2023

Based on Treatment segmentation, is Highly Active Antiretroviral Therapy (HAART) was the leading type in 2023

Based on Diagnostic segmentation, Biopsy was the leading type in 2023

based on region, North America was the leading revenue generator in 2023

Kaposi Sarcoma Market- Segmentation Analysis:

The Global Kaposi Sarcoma Market is segmented on the basis of Product Type, Treatment, Diagnostic, End User, and Region.

The market is divided into three categories based on product type: Epidemic (AIDS Associated) Kaposi Sarcoma, Classic (Mediterranean) Kaposi Sarcoma, Endemic (African) Kaposi Sarcoma, Iatrogenic (Transplant-Related) Kaposi Sarcoma. The most prominent segment in the Kaposi Sarcoma market is the Epidemic (AIDS Associated) Kaposi Sarcoma. This form of the disease has become the most significant due to the high prevalence of HIV/AIDS, which is a major risk factor for developing Kaposi Sarcoma. With the ongoing global AIDS epidemic, this type of Kaposi Sarcoma remains a critical concern, driving the demand for targeted treatments and research. The other types, while important, do not match the prevalence and impact of the epidemic variant.

The market is divided into six categories based on Treatment: Highly Active Antiretroviral Therapy (HAART), Radiation Therapy, Surgery, Cryosurgery, Chemotherapy, Biological Therapy. The most prominent treatment segment in the Kaposi Sarcoma market is Highly Active Antiretroviral Therapy (HAART). HAART is significant because it addresses the underlying HIV/AIDS infection, which is a major risk factor for Kaposi Sarcoma. Effective management of HIV through HAART can lead to significant improvements in Kaposi Sarcoma outcomes by controlling the virus and reducing the prevalence of related complications. While other treatments like Radiation Therapy, Surgery, and Chemotherapy are also important, HAART's role in managing the root cause of AIDS-associated Kaposi Sarcoma makes it the dominant approach.

Kaposi Sarcoma Market- Geographical Insights

The North American market for Kaposi's sarcoma (KS) treatment is influenced by several key factors. The prevalence of KS, primarily linked to HIV/AIDS, impacts market dynamics, with the majority of cases seen in the U.S. and Canada. Advances in antiretroviral therapy (ART) have improved KS outcomes, reducing the market demand for specific KS treatments. However, the need for effective therapies continues due to ongoing cases and relapses. Research and development in targeted therapies and clinical trials are contributing to market growth. The presence of major pharmaceutical companies and research institutions enhances the development of new treatments. Regulatory frameworks, healthcare policies, and access to healthcare services also play a crucial role in shaping the market landscape. Overall, while the market is niche, it is supported by continuous innovation and a focus on improving patient outcomes.

Kaposi Sarcoma Market- Competitive Landscape:

The Kaposi sarcoma market is driven by key players including Gilead Sciences, Bristol-Myers Squibb, Merck & Co., and Pfizer Inc., who are deeply involved in HIV/AIDS and oncology therapies. Other notable companies like Novartis AG, Roche Holding AG, and Eli Lilly contribute through their oncology research. Market dynamics include a focus on antiviral, targeted, and immunotherapies, with significant investments in R&D. Regulatory challenges and the rare nature of Kaposi sarcoma impact market growth. Opportunities lie in personalized and combination therapies. The competitive landscape is shaped by ongoing innovations and advancements in treatment strategies.

Recent Developments:

In July 2024, The USFDA approved ForDoz's injection, which contains doxorubicin hydrochloride in liposome form, for use in treating certain cancers. This formulation aims to improve the drug's delivery and reduce side effects compared to traditional doxorubicin..

In February 2023, Researchers at the University of North Carolina School of Medicine have discovered a protein that helps the Epstein-Barr virus (EBV) and the Kaposi sarcoma-associated herpesvirus (KSHV) cause disease and spread.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL KAPOSI SARCOMA MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Gilead Sciences
  • Bristol-Myers Squibb
  • Merck & Co.
  • Pfizer Inc.
  • Novartis AG
  • Roche Holding AG
  • Eli Lilly and Company
  • Amgen Inc.
  • Celgene Corporation (now part of Bristol-Myers Squibb)
  • AbbVie Inc.
  • Johnson & Johnson
  • Regeneron Pharmaceuticals
  • Incyte Corporation
  • Sandoz (a Novartis division)
  • Alimera Sciences

GLOBAL KAPOSI SARCOMA MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Epidemic (AIDS Associated) Kaposi Sarcoma
  • Classic (Mediterranean) Kaposi Sarcoma
  • Endemic (African) Kaposi Sarcoma
  • Iatrogenic (Transplant-Related) Kaposi Sarcoma

GLOBAL KAPOSI SARCOMA MARKET, BY TREATMENT- MARKET ANALYSIS, 2019 - 2032

  • Highly Active Antiretroviral Therapy (HAART)
  • Radiation Therapy
  • Surgery
  • Cryosurgery
  • Chemotherapy
  • Biological Therapy

GLOBAL KAPOSI SARCOMA MARKET, BY DIAGNOSTIC- MARKET ANALYSIS, 2019 - 2032

  • Bronchoscopy
  • Gastrointestinal Endoscopy
  • Biopsy
  • Others

GLOBAL KAPOSI SARCOMA MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Homecare
  • Others

GLOBAL KAPOSI SARCOMA MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Kaposi sarcoma Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Kaposi sarcoma Market Snippet by Product Type
    • 2.1.2. Kaposi sarcoma Market Snippet by Treatment
    • 2.1.3. Kaposi sarcoma Market Snippet by Diagnostic
    • 2.1.4. Kaposi sarcoma Market Snippet by End User
    • 2.1.5. Kaposi sarcoma Market Snippet by Country
    • 2.1.6. Kaposi sarcoma Market Snippet by Region
  • 2.2. Competitive Insights

3. Kaposi sarcoma Key Market Trends

  • 3.1. Kaposi sarcoma Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Kaposi sarcoma Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Kaposi sarcoma Market Opportunities
  • 3.4. Kaposi sarcoma Market Future Trends

4. Kaposi sarcoma Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Kaposi sarcoma Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Kaposi sarcoma Market Landscape

  • 6.1. Kaposi sarcoma Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Kaposi sarcoma Market - By Product Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product Type, 2023 & 2032 (%)
    • 7.1.2. Epidemic (AIDS Associated) Kaposi Sarcoma
    • 7.1.3. Classic (Mediterranean) Kaposi Sarcoma
    • 7.1.4. Endemic (African) Kaposi Sarcoma
    • 7.1.5. Iatrogenic (Transplant-Related) Kaposi Sarcoma

8. Kaposi sarcoma Market - By Treatment

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Treatment, 2023 & 2032 (%)
    • 8.1.2. Highly Active Antiretroviral Therapy (HAART)
    • 8.1.3. Radiation Therapy
    • 8.1.4. Surgery
    • 8.1.5. Cryosurgery
    • 8.1.6. Chemotherapy
    • 8.1.7. Biological Therapy

9. Kaposi sarcoma Market - By Diagnostic

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Diagnostic, 2023 & 2032 (%)
    • 9.1.2. Bronchoscopy
    • 9.1.3. Gastrointestinal Endoscopy
    • 9.1.4. Biopsy
    • 9.1.5. Others

10. Kaposi sarcoma Market - By End User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Treatment, 2023 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Homecare
    • 10.1.4. Others

11. Kaposi sarcoma Market- By Geography

  • 11.1. Introduction
    • 11.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 11.2. North America
    • 11.2.1. Overview
    • 11.2.2. Kaposi sarcoma Key Manufacturers in North America
    • 11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.2.5. North America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.2.6. North America Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
    • 11.2.7. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.2.8. U.S.
      • 11.2.8.1. Overview
      • 11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.8.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.8.4. U.S. Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.2.8.5. U.S. Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.2.8.6. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.2.9. Canada
      • 11.2.9.1. Overview
      • 11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.2.9.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.2.9.4. Canada Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.2.9.5. Canada Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.2.9.6. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.3. Europe
    • 11.3.1. Overview
    • 11.3.2. Kaposi sarcoma Key Manufacturers in Europe
    • 11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.3.5. Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.3.6. Europe Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
    • 11.3.7. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.8. Germany
      • 11.3.8.1. Overview
      • 11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.8.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.8.4. Germany Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.8.5. Germany Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.3.8.6. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.9. Italy
      • 11.3.9.1. Overview
      • 11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.9.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.9.4. Italy Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.9.5. Italy Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.3.9.6. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.10. United Kingdom
      • 11.3.10.1. Overview
      • 11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.10.3. United Kingdom Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.10.4. United Kingdom Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.10.5. United Kingdom Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.3.10.6. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.11. France
      • 11.3.11.1. Overview
      • 11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.11.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.11.4. France Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.11.5. France Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.3.11.6. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.12. Russia
      • 11.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.12.2. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.12.3. Russia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.12.4. Russia Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.3.12.5. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.13. Netherlands
      • 11.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.13.2. Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.13.3. Netherlands Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.13.4. Netherlands Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.3.13.5. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.14. Sweden
      • 11.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.14.2. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.14.3. Sweden Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.14.4. Sweden Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.3.14.5. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.15. Poland
      • 11.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.15.2. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.15.3. Poland Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.15.4. Poland Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.3.15.5. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.3.16. Rest of Europe
      • 11.3.16.1. Overview
      • 11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.3.16.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.3.16.4. Rest of the Europe Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.3.16.5. Rest of the Europe Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.3.16.6. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.4. Asia Pacific (APAC)
    • 11.4.1. Overview
    • 11.4.2. Kaposi sarcoma Key Manufacturers in Asia Pacific
    • 11.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.4.4. Asia Pacific Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.4.5. Asia Pacific Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.4.6. Asia Pacific Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
    • 11.4.7. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.8. India
      • 11.4.8.1. Overview
      • 11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.8.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.8.4. India Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.8.5. India Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.4.8.6. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.9. China
      • 11.4.9.1. Overview
      • 11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.9.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.9.4. China Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.9.5. China Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.4.9.6. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.10. Japan
      • 11.4.10.1. Overview
      • 11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.10.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.10.4. Japan Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.10.5. Japan Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.4.10.6. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.11. South Korea
      • 11.4.11.1. Overview
      • 11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.11.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.11.4. South Korea Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.11.5. South Korea Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.4.11.6. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.12. Australia
      • 11.4.12.1. Overview
      • 11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.12.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.12.4. Australia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.12.5. Australia Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.4.12.6. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.13. Thailand
      • 11.4.13.1. Overview
      • 11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.13.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.13.4. Thailand Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.13.5. Thailand Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.4.13.6. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.14. Indonesia
      • 11.4.14.1. Overview
      • 11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.14.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.14.4. Indonesia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.14.5. Indonesia Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.4.14.6. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.15. Philippines
      • 11.4.15.1. Overview
      • 11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.15.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.15.4. Philippines Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.15.5. Philippines Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.4.15.6. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.4.16. Rest of APAC
      • 11.4.16.1. Overview
      • 11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.4.16.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.4.16.4. Rest of APAC Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.4.16.5. Rest of APAC Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.5. Latin America
    • 11.5.1. Overview
    • 11.5.2. Kaposi sarcoma Key Manufacturers in Latin America
    • 11.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.5.4. Latin America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.5.5. Latin America Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.5.6. Latin America Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
    • 11.5.7. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.8. Brazil
      • 11.5.8.1. Overview
      • 11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.8.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.8.4. Brazil Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.8.5. Brazil Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.5.8.6. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.9. Mexico
      • 11.5.9.1. Overview
      • 11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.9.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.9.4. Mexico Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.9.5. Mexico Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.5.9.6. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.10. Argentina
      • 11.5.10.1. Overview
      • 11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.10.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.10.4. Argentina Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.10.5. Argentina Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.5.10.6. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.11. Colombia
      • 11.5.11.1. Overview
      • 11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.11.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.11.4. Colombia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.11.5. Colombia Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.5.11.6. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.5.12. Rest of LATAM
      • 11.5.12.1. Overview
      • 11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.5.12.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.5.12.4. Rest of LATAM Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.5.12.5. Rest of LATAM Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 11.6. Middle East and Africa
    • 11.6.1. Overview
    • 11.6.2. Kaposi sarcoma Key Manufacturers in Middle East and Africa
    • 11.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 11.6.4. Middle East and Africa Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 11.6.5. Middle East and Africa Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
    • 11.6.6. Middle East and Africa Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
    • 11.6.7. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.8. Saudi Arabia
      • 11.6.8.1. Overview
      • 11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.8.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.8.4. Saudi Arabia Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.8.5. Saudi Arabia Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.9. United Arab Emirates
      • 11.6.9.1. Overview
      • 11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.9.3. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.9.4. United Arab Emirates Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.9.5. United Arab Emirates Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.10. Israel
      • 11.6.10.1. Overview
      • 11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.10.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.10.4. Israel Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.10.5. Israel Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.6.10.6. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.11. Turkey
      • 11.6.11.1. Overview
      • 11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.11.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.11.4. Turkey Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.11.5. Turkey Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.6.11.6. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.12. Algeria
      • 11.6.12.1. Overview
      • 11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.12.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.12.4. Algeria Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.12.5. Algeria Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.6.12.6. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.13. Egypt
      • 11.6.13.1. Overview
      • 11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.13.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.13.4. Egypt Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.13.5. Egypt Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.6.13.6. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 11.6.14. Rest of MEA
      • 11.6.14.1. Overview
      • 11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 11.6.14.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 11.6.14.4. Rest of MEA Market Size and Forecast, By Treatment, 2019 - 2032 (US$ Million)
      • 11.6.14.5. Rest of MEA Market Size and Forecast, By Diagnostic, 2019 - 2032 (US$ Million)
      • 11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

12. Key Vendor Analysis- Kaposi sarcoma Industry

  • 12.1. Competitive Dashboard
  • 12.2. Company Profiles
    • 12.2.1. Gilead Sciences
    • 12.2.2. Bristol-Myers Squibb
    • 12.2.3. Merck & Co.
    • 12.2.4. Pfizer Inc.
    • 12.2.5. Novartis AG
    • 12.2.6. Roche Holding AG
    • 12.2.7. Eli Lilly and Company
    • 12.2.8. Amgen Inc.
    • 12.2.9. Celgene Corporation (now part of Bristol-Myers Squibb)
    • 12.2.10. AbbVie Inc.
    • 12.2.11. Johnson & Johnson
    • 12.2.12. Regeneron Pharmaceuticals
    • 12.2.13. Incyte Corporation
    • 12.2.14. Sandoz (a Novartis division)
    • 12.2.15. Alimera Sciences

13. 360 Degree Analyst View

14. Appendix

  • 14.1. Research Methodology
  • 14.2. References
  • 14.3. Abbreviations
  • 14.4. Disclaimer
  • 14.5. Contact Us